Olympus reviewed the following literature titled "technical and clinical success rates of wallflex duodenal stents in unresectable malignant gastric outlet obstruction.A retrospective observational study from a tertiary cancer hospital in india".This study to find the technical and clinical success, and complication rates of duodenal stenting in such patients presented at india¿s largest tertiary care cancer hospital.Technical and clinical success rates were 98.13% and 91.42%, respectively.Complications included bleeding in 12, pancreatitis in 4, and sedation-related complications in 25 of the patients.In the mean follow-up period of 120 days, recurrence of obstructive symptoms was observed in 66 of the patients.Tumor in growth in 59.09%, food impaction in 31.81%, and migration of the stent in 15.15% of patients were reasons for recurrence.The median time between clinical success and recurrence of obstructive symptoms was 148 days (95% confidence interval (ci): 0¿328).Placement of an enteral wallflex stent in patients with malignant goo is a practical, easy, and safe alternative to surgical gastrojejunostomy in malignant goo.Type of adverse events/number of patients: procedure- related bleeding -12 patients.Mild post-procedural pancreatitis - 4 patients.Stent migrations - 10 patients.Mild to moderate pain in the abdomen - 35 patients.Sedation-related complications - 8 patients.Such as hypotension, desaturation, and aspiration pneumonia etc.Death - no reported count.This literature article requires 2 reports.The related patient identifiers are as follows: (b)(6): tjf-150; (b)(6): cf-q160s.This medwatch report is for patient identifier (b)(6).The deaths and abdominal pain were determined to be not reportable.There is no report of any olympus device malfunction in any procedure described in this study.
|
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, the relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
|